Elanco Animal Health Incorporated
NYSE•ELAN
CEO: Mr. Jeffrey N. Simmons
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Listing Date: 2018-09-20
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Contact Information
Market Cap
$10.89B
P/E (TTM)
-46.7
33.3
Dividend Yield
--
52W High
$27.72
52W Low
$9.32
52W Range
Rank55Top 80.0%
2.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$1.14B+0.00%
4-Quarter Trend
EPS
-$0.56+0.00%
4-Quarter Trend
FCF
$46.00M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Revenue Grows Six Percent Total revenue reached $4,715M in 2025, marking a 6% increase driven by volume and pricing across segments.
Gross Margin Remains Flat Gross profit increased 6% to $2,593M; gross margin percentage held steady at 55.0% versus 54.9% in 2024.
Debt Profile Improved Total debt decreased to $3,762M by year-end 2025 following October refinancing activities and significant repayments.
New Products Drive Volume Higher volumes driven by new products like Credelio Quattro and Zenrelia contributed to Pet Health revenue growth.
Risk Factors
Significant Net Loss Recorded Reported net loss of ($232)M in 2025 contrasts sharply with $338M income reported in the prior fiscal year.
Restructuring Costs Increase Asset impairment and restructuring charges rose 58% to $237M, reflecting costs from the authorized 2025 Restructuring Plan.
Intense Industry Competition Highly competitive animal health industry faces pressure from generic products and potential pricing power erosion.
Manufacturing and Supply Risks Operations face risks from manufacturing capacity imbalances, potential shortages, and regulatory scrutiny on antibiotic use.
Outlook
Executing 2025 Restructuring Plan Plan targets margin expansion and footprint optimization, expecting $25M savings in 2026 from facility closures.
Farm Animal Portfolio Growth Anticipate launching Befrena in Q2 2026; subsequent event includes acquiring AHV to boost cattle product portfolio.
Continued R&D Investment R&D expenses increased 7% to $368M, supporting pipeline development via internal efforts, partnerships, and acquisitions.
Capital Spending Forecast Anticipate 2026 capital expenditures between $175M and $200M, following $276M spent in 2025 for facility expansion.
Peer Comparison
Revenue (TTM)
$45.08B
$14.30B
$5.94B
Gross Margin (Latest Quarter)
97.8%
95.6%
70.8%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| RVMD | $29.34B | -23.6 | -63.1% | 6.7% |
| MRNA | $18.13B | -6.4 | -30.1% | 15.5% |
| VTRS | $17.43B | -4.9 | -23.0% | 39.5% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-1.4%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
75%
Volatile Cash Flow
Deep Research
Next earnings:May 5, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data